Traces the development of the U.S. regulatory policy on the pharmaceutical industry during the twentieth century. An important issue is the steady shift away leave from a policy of ‘the buyer beware “to create a complex and time-consuming review process, managed by the U.S. Food and Drug Administration, in which both the safety and efficacy of any new drug must be shown prior to the sale in the United States. The basic economics of the pharmaceutical business as a covered … Read more »

Traces the development of the U.S. regulatory policy on the pharmaceutical industry during the twentieth century. An important issue is the steady shift away leave from a policy of ‘the buyer beware “to create a complex and time-consuming review process, managed by the U.S. Food and Drug Administration, in which both the safety and efficacy of any new drug must be shown prior to the sale in the United States. The basic economics of the pharmaceutical business are as well as the trend towards more emphasis on both marketing and R & D covered during the course of the century. Controversial issues of drug pricing, patent policy, and access to experimental drugs in the era of AIDS are explored as well. Contains a set of statistical tables and graphs of key indicators for the pharmaceutical industry in the postwar period.
«Hide

from
Willis Emmons,
Jeremiah O’Regan,
Monica Brand
25 pages.
Publication Date: Sep 10, 1991. Prod #: 792 002 PDF-ENG
Note on the regulation of the pharmaceutical industry HBR case solution

[related_post themes="flat"]